CaniLeish (Leishmania infantum excreted secreted...) – Conditions or restrictions regarding supply and use - QI070AO

Updated on site: 08-Feb-2018

Medication name: CaniLeish
ATC: QI070AO
Substance: Leishmania infantum excreted secreted proteins
Manufacturer: Virbac S.A

A.MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substance

VIRBAC

1ère avenue – 2065 m – L.I.D. 06516 Carros

France

Name and address of the manufacturer responsible for batch release

VIRBAC

1ère avenue – 2065 m – L.I.D. 06516 Carros

France

B.CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE

To be supplied only on veterinary prescription.

According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, Member States prohibit or may prohibit the import, sale, supply and/or use of the veterinary medicinal product on the whole or part of their territory if it is established that:

a)the administration of the veterinary medicinal product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.

b)the disease to which the veterinary medicinal product is intended to confer immunity is largely absent from the territory.

C.STATEMENT OF THE MRLs

Not applicable.

Comments